Found 1665 clinical trials
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)
(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these
- 115 views
- 15 Apr, 2019
- 1 location
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia (CLL) is a cancer of white blood cells. It is also called small lymphocytic lymphoma (SLL). It causes tiredness, night sweats
- 348 views
- 23 Nov, 2020
- 1 location
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma
- 782 views
- 23 Nov, 2020
- 5 locations
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Background: Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of abnormal B cells that often affect elderly patients. Studies have
- 169 views
- 15 Apr, 2019
- 1 location
Response to the HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune
- 59 views
- 09 Apr, 2019
- 1 location
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy
lymphocytic lymphoma (SLL). Eligibility: Adults ages 18 years and older with CLL or SLL who are not being treated for CLL or who are getting certain treatments.
- 228 views
- 09 Apr, 2019
- 1 location
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma
This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low grade NHL. Patients with NHL will be enrolled and receive G100 to an accessable tumor mass. Clinical response will be evaluated in the injected lesion and systemic (abscopal) responses will be evaluated in distal …
- 282 views
- 22 Dec, 2020
- 31 locations
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
refractory B-cell lymphoma.
- 86 views
- 10 May, 2022
- 21 locations
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- 95 views
- 10 May, 2022
- 2 locations
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
- 8 views
- 25 Mar, 2021
- 1 location